ISIN | LU2334253387 |
---|---|
No. de valeur | |
Bloomberg Global ID | |
Nom de fond | Bellevue Healthcare Strategy U2 EUR |
Prestataire de fonds |
Bellevue Asset Management AG
Zürich, Suisse Téléphone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Prestataire de fonds | Bellevue Asset Management AG |
Représentant en Suisse |
Waystone Fund Services (Switzerland) SA Lausanne Téléphone: 0041213111781 |
Distributeur(s) |
Bank am Bellevue AG Küsnacht Téléphone: +41 44 267 67 67 |
Classe d'actifs | Fonds en actions |
EFC Catégorie | |
Catégorie de parts | Accumulation |
Pays d'origine | Luxembourg |
Conditions d'émission de parts | Combinaison de commission d'émission en faveur de la direction du fonds et frais de transaction en faveur du fonds |
Conditions de rachat de parts | Combinaison de commission de rachat en faveur de la direction du fonds et frais de transaction en faveur du fonds |
Stratégie d'investissement *** | The Sub-fund is an actively managed equity fund. It is based on the Bellevue Healthcare Strategy that has been in existence since 2007. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two-thirds of the net assets of Bellevue Healthcare Strategy in a portfolio of carefully chosen shares and other equity securities of companies in the healthcare industry, or companies whose main activity consists of holding shares in such companies or financing such companies and who have their registered office or carry out the majority of their economic activity in recognised countries. |
Particularités |
Prix actuel * | 130.46 EUR | 05.09.2024 |
---|---|---|
Prix précédent * | 132.10 EUR | 04.09.2024 |
Max 52 semaines * | 133.46 EUR | 30.08.2024 |
Min 52 semaines * | 112.89 EUR | 27.10.2023 |
NAV * | 130.46 EUR | 05.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Prix minimal indicatif | ||
Actifs du fonds *** | 332'136'191 | |
Actifs de la classe *** | ||
Trading Information SIX |
YTD Performance | +9.68% |
29.12.2023 - 05.09.2024
29.12.2023 05.09.2024 |
---|---|---|
YTD Performance (en CHF) | +10.83% |
29.12.2023 - 05.09.2024
29.12.2023 05.09.2024 |
1 mois | +5.63% |
05.08.2024 - 05.09.2024
05.08.2024 05.09.2024 |
3 mois | +3.87% |
05.06.2024 - 05.09.2024
05.06.2024 05.09.2024 |
6 mois | +6.16% |
05.03.2024 - 05.09.2024
05.03.2024 05.09.2024 |
1 an | +7.50% |
05.09.2023 - 05.09.2024
05.09.2023 05.09.2024 |
2 ans | +4.57% |
06.09.2022 - 05.09.2024
06.09.2022 05.09.2024 |
3 ans | -2.58% |
07.09.2021 - 05.09.2024
07.09.2021 05.09.2024 |
5 ans | +1.72% |
15.06.2021 - 05.09.2024
15.06.2021 05.09.2024 |
Quota de participation de capital en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Part de la fortune du fonds en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quota d'immobilier en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Vertex Pharmaceuticals Inc | 3.40% | |
---|---|---|
Eli Lilly and Co | 3.33% | |
Regeneron Pharmaceuticals Inc | 3.24% | |
UnitedHealth Group Inc | 3.20% | |
HCA Healthcare Inc | 3.15% | |
Insulet Corp | 3.14% | |
McKesson Corp | 3.12% | |
IQVIA Holdings Inc | 2.99% | |
Boston Scientific Corp | 2.96% | |
UCB SA | 2.83% | |
Dernière mise à jour des données | 31.07.2024 |
TER | 0.92% |
---|---|
Date TER | 29.01.2021 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.60% |
Ongoing Charges *** | 0.96% |
SRRI ***
|
|
Date SRRI *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |